Aurora Cannabis, a Canadian cannabis producer, has seen its stock rise 30% year-to-date, driven by positive third-quarter fiscal results for 2025. The company reported earnings and sales that exceeded analysts’ expectations, reflecting its strong position in the evolving medical cannabis sector.
In the third quarter, Aurora’s medical cannabis revenue reached C$68.1 million, marking a 51% increase from the previous year. This segment now constitutes over 75% of the company’s total revenue, highlighting its strategic focus on medical cannabis. Notably, sales from international markets more than doubled, reaching $40.9 million, with major growth in regions like Australia, Germany, Poland, and the United Kingdom. This expansion is crucial as Aurora faces increasing competition in the Canadian market.
The company’s improved sales contributed to an adjusted gross margin of 74% in the medical segment, up from 63% the previous year. This growth in margins stems from higher selling prices, cost reductions, and better production efficiencies, allowing Aurora to report a profit after experiencing losses in the prior year.
Looking forward, Aurora anticipates continued growth in international medical cannabis sales in the upcoming fiscal quarter, aligning with projections that the global medical cannabis market will exceed $130 billion by 2032 due to rising acceptance for therapeutic uses.
However, Aurora’s recreational cannabis business has not fared as well. Revenue from this segment has declined, primarily due to heightened competition and regulatory challenges within Canada, which have affected pricing power and brand differentiation. In response, Aurora has reduced its involvement in the consumer market by closing underperforming facilities and cutting jobs to prioritize profitability in the medical segment.
The cannabis market remains competitive, with other companies like Canopy Growth and Tilray Brands also pursuing international expansion and cost-cutting strategies. As Aurora strengthens its presence in international markets, it may face increased competition from these peers, potentially leading to further consolidation in the industry.
So far this year, Aurora’s stock has outperformed the broader cannabis industry, which has seen a 5% increase. Analysts have kept their earnings per share estimates stable for 2025 and 2026, indicating a cautious outlook for the company.
Investors interested in Aurora Cannabis may want to hold off on purchasing more shares until the company releases its fiscal fourth-quarter results, which will shed more light on the sustainability of its international growth and the potential for continued margin expansion despite challenges in the consumer segment.
English 
Spanish 
German 
Czech